Swiss Rockets
Swiss Rockets Group, founded in 2018, is an innovative biotech umbrella company with a portfolio of niche-leading biotech companies. It focuses on developing groundbreaking medicines for cancer, infectious diseases, autoimmune disorders, and viral diseases, using innovative and pioneering methods. The company aims to transform healthcare by identifying, investing in, and cultivating promising biotech startups across Switzerland, Europe, and the US. It provides mentorship, funding, legal and regulatory guidance, access to industry experts, and state-of-the-art facilities to accelerate growth and impact in the biotech industry. Additionally, Swiss Rockets has launched Torqur, a Swiss clinical-stage biotech company dedicated to developing potent PI3K/mTOR inhibitors for targeted cancer therapies, supporting patients' quality of life and extended survival.
Industries
Nr. of Employees
small (1-50)
Swiss Rockets
Basel, Basel-Stadt, Switzerland, Europe
Products
Intranasal live‑attenuated and single‑cycle viral vaccine candidates
Nasal spray vaccine candidates based on engineered attenuated or replication‑incompetent viruses designed to induce mucosal IgA and systemic immunity, evaluated in preclinical studies and advanced toward early clinical trials.
Clinical‑stage pan‑PI3K/mTOR small‑molecule program (oral and topical formulations)
Development program for balanced pan‑PI3K/mTOR inhibitors formulated for oral and topical administration, advanced into clinical evaluation with a biomarker‑guided approach for oncology and dermatology indications.
Targeted radioligand therapy development using high‑potency radioisotopes
Preclinical radiopharmaceutical programs evaluating therapeutic radioisotopes to increase tumor dose delivery and assessing safety and efficacy outcomes, alongside efforts to secure isotope supply chains for clinical use.
Intranasal live‑attenuated and single‑cycle viral vaccine candidates
Nasal spray vaccine candidates based on engineered attenuated or replication‑incompetent viruses designed to induce mucosal IgA and systemic immunity, evaluated in preclinical studies and advanced toward early clinical trials.
Clinical‑stage pan‑PI3K/mTOR small‑molecule program (oral and topical formulations)
Development program for balanced pan‑PI3K/mTOR inhibitors formulated for oral and topical administration, advanced into clinical evaluation with a biomarker‑guided approach for oncology and dermatology indications.
Targeted radioligand therapy development using high‑potency radioisotopes
Preclinical radiopharmaceutical programs evaluating therapeutic radioisotopes to increase tumor dose delivery and assessing safety and efficacy outcomes, alongside efforts to secure isotope supply chains for clinical use.
Services
Incubator and accelerator support
Mentorship, early‑stage funding access, scientific and business expertise, regulatory guidance, and provision of shared office, laboratory and manufacturing facilities to portfolio startups.
Management and drug development advisory services
Interim executive management and advisory support covering discovery, clinical operations, regulatory strategy, manufacturing partnerships and business development for clinical‑stage and preclinical companies.
Clinical manufacturing process development and CDMO partnership management
Development and optimization of clinical manufacturing processes, rapid generation of clinical‑trial material and management of collaborations with contract development and manufacturing organizations.
Incubator and accelerator support
Mentorship, early‑stage funding access, scientific and business expertise, regulatory guidance, and provision of shared office, laboratory and manufacturing facilities to portfolio startups.
Management and drug development advisory services
Interim executive management and advisory support covering discovery, clinical operations, regulatory strategy, manufacturing partnerships and business development for clinical‑stage and preclinical companies.
Clinical manufacturing process development and CDMO partnership management
Development and optimization of clinical manufacturing processes, rapid generation of clinical‑trial material and management of collaborations with contract development and manufacturing organizations.
Expertise Areas
- Biotech incubator and accelerator services
- Clinical development and trial management
- Vaccine research and development (mucosal/intranasal platforms)
- Small‑molecule oncology discovery (PI3K/mTOR)
Key Technologies
- Live‑attenuated and single‑cycle viral vaccine platforms
- Synthetic molecular biology for viral attenuation (sequence engineering)
- Pan‑PI3K/mTOR small‑molecule inhibitors
- Topical and oral small‑molecule formulation